

New class of cancer vaccines
based on an off-the-shelf Antigen
Presenting Cell line (PDC*line)



PDC*line
pharma

ADVANCED CANCER
VACCINES





Scale-up and spin-off of EFS (French Blood Bank)

- 43 people including seasoned executives from biotech / pharma industry
- Funding : ~ €61 M (31 M€ in equity and 30 M€ of non-dilutive money).



PDC*line

Our proprietary PDC*line has 3 key advantages

- A **cell line** of Dendritic Cells Very **easy to expand**
- **Plasmacytoid** Dendritic Cells Highly **potent antigen presenting cell**
- **Versatile** platform Broadly **applicable to any cancer**



Clinical stage: phase 1b academic feasibility study in Melanoma completed and phase 1b/2a for Non-Small Cell Lung Cancer ongoing



Current pipeline & Development Status

Pipeline

Product	Composition	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Partner
PDC*lung	6 shared tumor antigens	Non-Small Cell Lung Carcinoma	Phase 1b/2 Ongoing				LG Chem
PDC*neo	Neo-antigens	Colorectal Cancer					OncoDNA [®] THE CANCER THERANOSTIC COMPANY
PDC*uc	6 shared tumor antigens	Urothelial Carcinoma					
PDC*hcc	6 shared tumor antigens	Hepatocellular Carcinoma					
PDC*mel	4 shared tumor antigens	Cutaneous Melanoma	Phase 1b Academic Feasibility Study Completed				

Cell Line

Product	Composition	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Partner
PDC*line HLA-A*24							



Validating licensing agreement with **LG Chem** led to substantial Asian financial backing



LG Chem Life Sciences Company obtained **exclusive license** in South Korea and exclusive option in other Asian countries for the development and commercialization of PDC*lung for lung cancer (2019).

The total deal value of 108M€ (123M\$) plus **significant tiered royalties on net sales in Asia**

Deal led to the closing of a **20M€ B1 financing round** in Dec'2019 led by the blue-chip Asian VC Korean Investment Partners (KIP) and a **17.5M€ B2 financing round** in Dec'2021

 **Korea Investment Management Co., Ltd.**



 **Shinhan Financial Group**
Shinhan-Cognitive Start-up Fund



 **UTC** Union of Technology & Capital





Complementary team with track record Management



President & CEO

Eric HALIOUA (MS, MBA)

30-year experience in technology and start-up management. Former CEO of Promethera Biosciences, co-founder of Myosix (sold to Genzyme/Sanofi) & Murigenetics ; Board of Essencia/bio.be. Former principal of the international life sciences practice of Arthur D. Little based (Paris, Boston).



Co-founder & CSO

Joel PLUMAS (PhD)

30-year in Immuno-oncology, co-inventor of the PDC*line technology (patented), director the “Immunobiology and Immunotherapy of cancers” R&D lab of the French blood bank (EFS) until 2016. Developed the technology and coordinated its development up to phase I clinical trials in melanoma.



Co-founder,
COO & CFO

Laurent LEVY (MS, MBA)

20-year experience of finance & development in biotech, including 8 years as director of finance & development of a major Cancer Cluster (CLARA, France) where he set-up and managed a fund that supported 30 Proof-of-concept projects in oncology. Involved in the project since 2006 and co-founded the start-up in 2014.



VP Pharmaceutical
Operations & Quality

Claude DEDRY (Pharm. D)

Over 25-year experience in GMP manufacturing and quality control operations of vaccines and cell therapies (GSK vaccines, Promethera Biosciences...). Owner of CMDL Consulting (Belgium) that provides small, medium and big size companies with guidance.



Chief Medical Officer

Beatrice DE VOS (MD, PhD)

Over 30-year experience in executive positions of clinical research and medical affairs departments of major international pharmaceutical companies, including GSK Biologicals and Sanofi Pasteur. Oversaw clinical development programs of multiple novel immunotherapies.




PDC - LUNG -101 (PHASE I/II) : Evaluation of Safety, Immunological activity, and Clinical response of PDC*lung01 +/- anti-PD-1

Positioning of PDC*lung:
First line for metastatic stage Non Small Cell Lung Cancer patients in association with PD-L1 high in the tumor

		Cohort	Arm	# of patients	NSCLC Patient Criteria	Main Objectives
Phase	PDC*lung01 Mono	A1 Low dose	2M cells/peptide	6	<ul style="list-style-type: none"> • Stage IIa/IIb/IIIa after R0 resection • Adjuvant chemotherapy +/- radiotherapy 	<ul style="list-style-type: none"> • Safety & tolerability • Immune activity
		A2 High dose	20M cells/peptide	10		
Phase	Anti-PD-1 + PDC*lung01	B1 Low dose	2M cells/peptide + anti-PD-1	6	<ul style="list-style-type: none"> • Stage IV starting anti-PD-1 as first-line (TPS\geq50%) 	<ul style="list-style-type: none"> • Dose range • Clinical activity: <ul style="list-style-type: none"> - Overall Response Rate (ORR) - Median Progression Free Survival (mPFS) - Disease Control Rate (DCR)
		B2 High dose	20M cells/peptide + anti-PD-1	42		



Promising interim clinical activity results on three key parameters in NSCLC patients in first line in association with Pembrolizumab



- Number of Patients – B2 (High dose PDC*lung): n=19
- Keynote 042 – phase III clinical trial from merck with Pembrolizumab monotherapy in the same clinical

Cut-off July 2023



Series C Financing Summary

Target Raise Size	~70 to 90 M€
Securities Type	Equity
Financing Round	Series C
Estimated Close	4Q 2024
Use of Proceeds	<ul style="list-style-type: none">• PDC*lung - Phase 2b randomized trial (200 patients) operations through primary analysis, which is expected in 1Q 2028 (~59 to 79 M€)^{2,3}• PDC*neo - Phase 1b trial operations through primary analysis, which is expected in 4Q 2027 (~7 M€) Plus general R&D and corporate expenses
Cash Runway	Current financing to extend operating cash runway through 2Q 2028 (to fully cover the cost of randomized Phase 2 trial with PDC*lung)



Thank you!





PDC*line
pharma
ADVANCED CANCER
VACCINES

CONTACTS

Laurent LEVY **Eric HALIOUA**

Co-founder & COO President & CEO

M. +33 634 36 77 47 M. +32 474 05 7866

l.levy@pdc-line-pharma.com e.halioua@pdc-line-pharma.com



Key achievements since the foundation of the company

